Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00978822 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of Clevidipine to Control Hypertension in Patients Admitted With Aneurysmal Subarachnoid Hemorrhage
A Phase 2 study, sponsored by Henry Ford Health System.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT00978822 is a Phase 2 study that was terminated before completion, run by Henry Ford Health System. The registered enrollment target is 5 participants.
The verdict
NCT00978822, a Phase 2 study, was terminated before completion, sponsored by Henry Ford Health System.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
This study is designed to assess how rapidly and how safely Clevidipine can be used to control high Blood Pressure in patients with subarachnoid hemorrhage which is a type of brain bleed that happens because of a weak balloon like structure in one of the brain vessels. Control of blood pressure is of high value in preventing this balloon that ruptured and bled from rebleeding. The ultimate cure would be to shut down the aneurysm by a surgical procedure. Clevidipine is a drug that can lower blood pressure and it is given through the vein as a continuous infusion. It is a very short acting drug which is important in controlling labile blood pressure condition with rapid changes between up and down. This trial will test for its rapid actions and check for any side effects and possibly any other potential benefit.
Interventions
- DRUG Clevidipine butyrate injectable emulsion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2009-06 |
| Est. Completion | 2012-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00978822
The ClinicalTrials.gov registry entry for NCT00978822 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Henry Ford Health System, which has 234 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Clevidipine butyrate injectable emulsion is the first listed.
NCT00978822 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00978822 about?
NCT00978822 is a clinical study titled "Safety and Efficacy Study of Clevidipine to Control Hypertension in Patients Admitted With Aneurysmal Subarachnoid Hemorrhage". This study is designed to assess how rapidly and how safely Clevidipine can be used to control high Blood Pressure in patients with subarachnoid hemorrhage which is a type of brain bleed that happens because of a weak balloon like structure in one of the brain vessels. Control of blood pressure is o...
What is the current status of trial NCT00978822?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2009-06. Estimated completion is 2012-12.
What interventions are being tested in trial NCT00978822?
The interventions under investigation include: Clevidipine butyrate injectable emulsion (DRUG).
Who is sponsoring clinical trial NCT00978822?
This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.